Form 4: Tarsus CHRO Sells Shares for Tax Obligations

Tarsus Pharmaceuticals' Chief Human Resources Officer, Dianne C. Whitfield, sold shares to cover tax withholding obligations from RSU vesting.

Summary

• Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, Inc., reported sales of common stock.
• A total of 12,274 shares were sold across three transactions on March 17, 18, and 19, 2026.
• The sales were executed at prices of $69.42, $68.71, and $67.00 per share, respectively.
• These transactions were non-discretionary "sell to cover" sales, mandated by the issuer to satisfy tax withholding obligations related to the vesting and settlement of Restricted Stock Units.
• Following these transactions, Dianne C. Whitfield beneficially owns 35,028 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine, non-discretionary transaction to cover tax obligations from RSU vesting, not an indicator of management's sentiment towards the company's future.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding Tarsus Pharmaceuticals, Inc.'s future performance or strategic direction.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units.
• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and routine occurrence for executives receiving equity compensation. These sales are typically non-discretionary and are executed solely to satisfy tax liabilities arising from the vesting of restricted stock units (RSUs), rather than reflecting a change in management's outlook on the company's prospects. Such transactions are standard practice across various industries for managing equity compensation.

Stakeholder Impact

• Minimal impact on shareholders as the sale is a routine, non-discretionary event for tax purposes and does not signal a change in company fundamentals or management confidence.

Key Dates

Recommendation

The reported insider sales are non-discretionary 'sell to cover' transactions, mandated to satisfy tax withholding obligations from RSU vesting. This is a routine event and does not reflect a change in the reporting person's confidence in Tarsus Pharmaceuticals, Inc. or its future prospects. Therefore, it provides no new fundamental information to warrant a change in investment posture, leading to a 'hold' recommendation.

Keywords

Tarsus Pharmaceuticals, TARS, Form 4, Insider Transaction, Stock Sale, RSU, Tax Withholding, Dianne C. Whitfield